Rezolute prices offering of about $100 million in common stock
FROM THE WIRE · GLOBENEWSWIRE.COM
Transaction led by Frazier Life Sciences with participation from new and existing funds REDWOOD CITY, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or the Company), a late-stage ultra-rare, metabolic disease company focused on treating…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishA roughly $100 million offering at $3.87 per share may weigh on the stock through dilution.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The offering includes 22,040,976 common shares at $3.87 each.
- 02Pre-funded warrants for up to 3,800,000 shares are included.
- 03The offering is led by Frazier Life Sciences.
- 04Rezolute is a biopharmaceutical company focused on hyperinsulinism.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets